Multiple Myeloma | Current Treatment | US | 2016
The multiple myeloma therapy market has witnessed considerable advances in recent years. Effective therapies such as Thalomid, Revlimid, Velcade, Pomalyst, and Kyprolis have transformed the treatment of this disease, and the treatment algorithms for multiple myeloma continue to evolve, driven by the 2015 approval of several novel, high-priced therapies with new mechanisms of action. This analysis provides insight on current and anticipated use of approved therapies for multiple myeloma and on hematologist-oncologists’ perception of these therapies.
Related Market Assessment Reports
Report
Eosinophilic Esophagitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Eosinophilic Esophagitis (US)
Eosinophilic esophagitis (EoE) is a chronic allergic inflammatory condition of the esophagus, marked by an accumulation of eosinophils. This can lead to difficulty swallowing and potentially…
Report
Metabolic Dysfunction-Associated Steatohepatitis – Unmet Need – Unmet Need – Metabolic Dysfunction-Associated Steatohepatitis (US/EU)
Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), has the potential to be a large and lucrative therapy market owing to the disease…
Report
Hepatocellular Carcinoma – Geographic Focus: China – Hepatocellular Carcinoma – China In-Depth (China)
The hepatocellular carcinoma therapy market in China is poised to experience significant growth, driven by an aging population and the high prevalence of hepatitis B and C infection. Angiogenesis…
